InspireMD Targets Q4 FDA Decisions While Cutting $9 Million in Annual Costs

Key Points

• InspireMD expects potential FDA decisions in Q4 2026 for the CGuard Prime 80 cmsystem for transcarotid artery revascularization, or TCAR, and its original CGuard carotid artery stenting, or CAS, system.
• The company has reduced its workforce by nearly 20% as part of an efficiency plan expected to create about $9 million in annual cost savings.
• Management expects to see the full run-rate effect of cost savings in Q4 2026, with partial savings beginning in Q3.
• Q2 2026 revenue was $1.77 million, while international revenue increased approximately 21% year over year.
• The CGuard Prime 135 cm recall created revenue credits and product-related charges that weighed on quarterly gross profit.
• InspireMD expects to resubmit its redesigned Prime 135 cm system to the FDA before year-end, with a targeted U.S. market return in the first half of 2027.

InspireMD, Inc. (Nasdaq: NSPR) expects key FDA decisions in the fourth quarter of 2026 as it restructures operations to reduce annual expenses by approximately $9 million. The company is working to rebuild its U.S. carotid-stent business after the voluntary recall of its CGuard Prime 135 cm delivery system affected second-quarter financial results.

 FDA Reviews Could Set the Pace for U.S. Carotid-Stent Growth

InspireMD is awaiting FDA decisions for two carotid-intervention products that could expand its U.S. market opportunity. The CGuard Prime 80 cm system is designed for TCAR procedures, a minimally invasive method for treating carotid artery disease. The original CGuard platform is intended for carotid artery stenting procedures.

Management said it expects potential FDA decisions in the fourth quarter of 2026. These timing expectations are based on the company’s regulatory discussions and are not guarantees of approval. The FDA could ask for more information, extend its review, or decline to clear either product.

If cleared, the devices could help InspireMD reestablish and broaden its U.S. commercial presence. However, the company will still need to execute product launches, build physician adoption, secure hospital access, and compete in the carotid-device market.

 CGuard Prime 135 Recall Pressured Revenue and Margins

The company’s voluntary recall of its CGuard Prime 135 cm delivery system had a meaningful impact on second-quarter results. InspireMD said the recall resulted in revenue credits, inventory-related charges, and an impairment expense that contributed to a reported gross loss.

The recall also made the company’s reported U.S. sales more difficult to interpret because the revenue credits reduced the quarter’s reported figures. Management said it is redesigning the 135 cm delivery system and intends to submit the updated product to the FDA before the end of 2026.

InspireMD is targeting a return of the Prime 135 cm product to the U.S. market in the first half of 2027. That timeline depends on final design validation, regulatory submission and review, and FDA clearance.

Workforce Reduction Is Designed to Preserve Cash Ahead of Product Launches

After the quarter ended, InspireMD implemented a cost-reduction program intended to align spending with its near-term regulatory and commercial priorities. The plan includes a workforce reduction of nearly 20% and is expected to reduce annual expenses by about $9 million.

The company expects to recognize a restructuring charge of roughly $900,000 to $1.2 million in the third quarter, mainly related to severance and other implementation costs. Management expects partial savings during Q3 and the full annualized savings effect in Q4.

For NSPR investors, the restructuring may extend the company’s financial runway and lower its cash burn. The company must also ensure that the smaller organization can support FDA submissions, product redevelopment, international operations, and a possible U.S. commercial expansion.

 International Revenue Growth Provides Support During U.S. Transition

InspireMD reported total second-quarter revenue of $1.77 million. International revenue increased roughly 21% from the prior-year period, which helped partially offset the disruption caused by the U.S. Prime 135 cm recall.

Management is also evaluating pricing and margin opportunities in international markets. Continued overseas growth could provide revenue support while the company awaits FDA action on its other products and advances the Prime 135 redesign.

Investors Await FDA Decisions and Evidence of Cost Savings

The next several quarters will be important for InspireMD. The company’s growth outlook depends on regulatory decisions for its CGuard product line, a successful redesign of the Prime 135 cm system, and its ability to show that the $9 million cost-savings program is reducing operating expenses.

Investors may watch for FDA updates in Q4 2026, the planned Prime 135 resubmission, the pace of U.S. commercial recovery, international sales growth, quarterly cash use, and the realized impact of the workforce-reduction plan.